Related references
Note: Only part of the references are listed.Managing Cancer Pain at the End of Life with Multiple Strong Opioids: A Population-Based Retrospective Cohort Study in Primary Care
Wei Gao et al.
PLOS ONE (2014)
Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial
Renee Romeo et al.
BRITISH JOURNAL OF PSYCHIATRY (2013)
Study of the use of antidepressants for depression in dementia: the HTA-SADD trial - a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine
S. Banerjee et al.
HEALTH TECHNOLOGY ASSESSMENT (2013)
Cost-Effectiveness of One Year Dementia Follow-Up Care by Memory Clinics or General Practitioners: Economic Evaluation of a Randomised Controlled Trial
Els Meeuwsen et al.
PLOS ONE (2013)
How to Include Informal Care in Economic Evaluations
Renske J. Hoefman et al.
PHARMACOECONOMICS (2013)
The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice
Ingrid Lekander et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2013)
An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom
Dennis Getsios et al.
ALZHEIMERS & DEMENTIA (2012)
Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation
Susanne Hartz et al.
BMC NEUROLOGY (2012)
REMCARE: reminiscence groups for people with dementia and their family caregivers - effectiveness and cost-effectiveness pragmatic multicentre randomised trial
R. T. Woods et al.
HEALTH TECHNOLOGY ASSESSMENT (2012)
The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model
M. Bond et al.
HEALTH TECHNOLOGY ASSESSMENT (2012)
Cost-effectiveness of memantine in moderate and severe Alzheimer's disease in Norway
B. Rive et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2012)
Cost-Effectiveness of Magnetic Resonance Imaging with a New Contrast Agent for the Early Diagnosis of Alzheimer's Disease
Maria Biasutti et al.
PLOS ONE (2012)
The Inclusion of Informal Care in Applied Economic Evaluation: A Review
Kacey Goodrich et al.
VALUE IN HEALTH (2012)
Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models
Balazs Nagy et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2011)
Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment
Gisela Kobelt et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2011)
Management of Patients with Malignant Bowel Obstruction and Stage IV Colorectal Cancer
Kimberly Moore Dalal et al.
JOURNAL OF PALLIATIVE MEDICINE (2011)
Health Effects in Significant Others: Separating Family and Care-Giving Effects
Ana Bobinac et al.
MEDICAL DECISION MAKING (2011)
Objective burden, resources, and other stressors among informal cancer caregivers: a hidden quality issue?
Michelle van Ryn et al.
PSYCHO-ONCOLOGY (2011)
Cost-Effectiveness of Biologics in Polyarticular-Course Juvenile Idiopathic Arthritis Patients Unresponsive to Disease-Modifying Antirheumatic Drugs
Wendy J. Ungar et al.
ARTHRITIS CARE & RESEARCH (2011)
Societal cost of rheumatoid arthritis patients in the US
Howard Birnbaum et al.
CURRENT MEDICAL RESEARCH AND OPINION (2010)
Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden
Ingrid Lekander et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2010)
Caring for and caring about: Disentangling the caregiver effect and the family effect
Ana Bobinac et al.
JOURNAL OF HEALTH ECONOMICS (2010)
Is the Societal Approach Wide Enough to Include Relatives? Incorporating Relatives ' Costs and Effects in a Cost-Effectiveness Analysis
Thomas Davidson et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2010)
Cost-Utility Analysis of Treatment Strategies in Patients With Recent-Onset Rheumatoid Arthritis
Wilbert B. van den Hout et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2009)
Cost Effectiveness of Rasagiline and Pramipexole as Treatment Strategies in Early Parkinson's Disease in the UK Setting An Economic Markov Model Evaluation
Alan Haycox et al.
DRUGS & AGING (2009)
Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden
Peter Lindgren et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2009)
Modeling the Cost-Effectiveness of Galantamine for Mild to Moderately Severe Alzheimer's Disease in Korea
Guk-Hee Suh
VALUE IN HEALTH (2009)
An overview of methods and applications to value informal care in economic evaluations of healthcare
Marc A. Koopmanschap et al.
PHARMACOECONOMICS (2008)
Caregiver-burden in Parkinson's disease is closely associated with psychiatric symptoms, falls, and disability
A Schrag et al.
PARKINSONISM & RELATED DISORDERS (2006)
Incorporating carer effects into economic evaluation
S Dixon et al.
PHARMACOECONOMICS (2006)
Implications of spillover effects within the family for medical cost-effectiveness analysis
A Basu et al.
JOURNAL OF HEALTH ECONOMICS (2005)
Burden of caregiving: Evidence of objective burden, subjective burden, and quality of life impacts on informal caregivers of patients with rheumatoid arthritis
WBF Brouwer et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2004)
Measuring costs in cost-utility analyses -: Variations in the literature
PW Stone et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2000)
Share Paper
